{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:58:46Z","timestamp":1794851926580,"version":"4.9.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,13]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Dermatologic toxicity has been reported as the most common immune-related side effect of programmed cell death 1 inhibitors. Previous reports related to Sintilimab include rash, pruritus, vitiligo, Stevens-Johnson syndrome, toxic epidermal necrolysis, and so on.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 66-year-old man was treated with Sintilimab as monotherapy for sigmoid colon cancer. After the second prescription, he developed a more severe and widespread rash.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The diagnose of erythema multiforme drug eruption induced by Sintilimab was considered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient received intravenous and oral methylprednisolone, routine antihistamines and topical gluccorticoids.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient\u2019s symptoms were gradually relieved during hospitalization and was discharged following resolution of symptoms. He refused to continue using Sintilimab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This is the first reported case of Sintilimab-induced erythema multiforme drug eruption. It is advisable to inform patients of potential dermatologic toxicity that may occur after using immune checkpoint inhibitors, so that we may prevent the further development of it and avoid the discontinuation of immune checkpoint inhibitors.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000035659","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:02:53Z","timestamp":1697230973000},"page":"e35659","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Sintilimab-induced erythema multiforme drug eruption in the treatment of sigmoid colon cancer: A case report and literature review"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9069-1615","authenticated-orcid":false,"given":"Mei","family":"Zhang","sequence":"first","affiliation":[{"name":"Guizhou University of Traditional Chinese Medicine, Guiyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqin","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second People\u2019s Hospital of Guiyang, Guiyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions.","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma.","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis.","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy.","volume":"8","author":"Vivek","year":"2017","journal-title":"Front Pharmacol"},{"key":"R5-20250504","first-page":"253","article-title":"A case of dermatitis bullosa caused by sintilimab in treating advanced lung adenocarcinoma.","volume":"41","author":"Yan","year":"2022","journal-title":"Chin J New Drugs Clin Rem"},{"key":"R6-20250504","first-page":"1290","article-title":"A case report: rare purpuric skin vasculitis induced by sintilimab.","volume":"42","author":"Wu","year":"2022","journal-title":"Chin J Hosp Pharm"},{"key":"R7-20250504","first-page":"263","article-title":"One case of toxic epidermal necrolysis caused by tumor immune checkpoint inhibition sintilimab.","volume":"41","author":"Shan","year":"2022","journal-title":"Herald Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2217\/imt-2021-0074","article-title":"Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review.","volume":"14","author":"Yang","year":"2022","journal-title":"Immunotherapy"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2147\/OTT.S353743","article-title":"Treatment of PD-1 inhibitor-associated toxic epidermal necrolysis: a case report and brief review.","volume":"15","author":"Zhao","year":"2022","journal-title":"Onco Targets Ther"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.21037\/atm-22-5925","article-title":"Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a case report and review of the literature.","volume":"10","author":"Yan","year":"2022","journal-title":"Ann Transl Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"989966","DOI":"10.3389\/fimmu.2022.989966","article-title":"Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: a case report.","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1065137","DOI":"10.3389\/fonc.2022.1065137","article-title":"Case Report: Toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma.","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2147\/CCID.S374449","article-title":"A case of systemic severe bullous pemphigoid caused by long-term sintilimab treatment for renal cell carcinoma.","volume":"15","author":"He","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"e15663","DOI":"10.1111\/dth.15663","article-title":"A case of sintilimab-induced SJS\/TEN: dermatologic adverse reactions associated with programmed cell death protein-1 inhibitors.","volume":"35","author":"Huang","year":"2022","journal-title":"Dermatol Ther"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1124730","DOI":"10.3389\/fonc.2023.1124730","article-title":"Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR\/MSS colorectal cancer.","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.explore.2023.02.008","article-title":"Successful treatment of immune-related lichenoid dermatitis by Weiling decoction in a patient with non-small cell lung cancer: a case report and review of literature.","volume":"19","author":"Liu","year":"2023","journal-title":"Explore (NY)"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CCID.S401286","article-title":"Adalimumab for sintilimab-induced toxic epidermal necrolysis in a patient with metastatic gastric malignancy: a case report and literature review.","volume":"16","author":"Zhang","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1099108","DOI":"10.3389\/fonc.2022.1099108","article-title":"Case report: immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: a report of three cases and a pooled analysis of individual patient data.","volume":"12","author":"Rao","year":"2023","journal-title":"Front Oncol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade.","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/JIPO.JIPO_20_18","article-title":"Being realistic and optimistic in curing cancer.","volume":"1","author":"Aung","year":"2018","journal-title":"J Immunotherap Precis Oncol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.2147\/IJGM.S295444","article-title":"Situs inversus totalis: a clinical review.","volume":"15","author":"Eitler","year":"2022","journal-title":"Int J Gen Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035659","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:13:48Z","timestamp":1746324828000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":21,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035659","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]}}}